# Head and Neck Squamous Cell Carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/head-and-neck-squamous-cell-carcinoma

> 10 upcoming FDA catalysts in head and Neck Squamous Cell Carcinoma: domvanalimab (GILD) on March 2027 (primary completion); domvanalimab (GILD) on Mar to Jun 2027 (topline data readout); petosemtamab (GMAB) on January 2028 (primary completion); petosemtamab (GMAB) on Jan to Apr 2028 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 2027 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | GILD | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06727565 (Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727565)) |
| Mar to Jun 2027 | [Domvanalimab topline data readout](https://sec-api.dev/pdufa/domvanalimab) | GILD | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06727565 (Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727565)) |
| January 2028 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06525220 (A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06525220)) |
| Jan to Apr 2028 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06525220 (A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06525220)) |
| February 2028 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06496178 (A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496178)) |
| Feb to May 2028 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06496178 (A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496178)) |
| August 2028 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082167)) |
| Aug to Nov 2028 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082167)) |
| October 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT07744126 (A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07744126)) |
| Oct 2029 to Jan 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT07744126 (A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07744126)) |

## Drugs

- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [Petosemtamab](https://sec-api.dev/pdufa/petosemtamab) (GMAB)
- [Zanzalintinib](https://sec-api.dev/pdufa/zanzalintinib) (EXEL)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/head-and-neck-squamous-cell-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Head and Neck Squamous Cell Carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/head-and-neck-squamous-cell-carcinoma

```bibtex
@misc{secapidev_indications_head_and_neck_squamous_cell_carcinoma_20261116,
  title        = {Head and Neck Squamous Cell Carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/head-and-neck-squamous-cell-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_head_and_neck_squamous_cell_carcinoma_20261116","title":"Head and Neck Squamous Cell Carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/head-and-neck-squamous-cell-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
